Tyrosine kinase inhibitorPhase 3 trialInvestigational
Capmatinib
How it works
Blocks the MET receptor on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— MET exon 14 skipping mutation
Efficacy
In clinical trials, around 68% of MET exon 14 skipping mutation patients achieved an objective response, with a median progression-free survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Capmatinib's Effectiveness in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.